Duodenal Ulcer Treatment Market Size & Share 2025 – 2034

Duodenal Ulcer Treatment Market Size

The global duodenal ulcer treatment market was estimated at USD 3.2 billion in 2024. The market is expected to grow from USD 3.3 billion in 2025 to USD 5.2 billion in 2034, at a CAGR of 5.1%. The growing prevalence of duodenal ulcers, driven by lifestyle factors such as poor dietary habits, smoking, and alcohol consumption, is fueling demand for effective therapeutic solutions.

According to an article published by the Public Library of Science (PLOS), peptic ulcers affect approximately 4 million individuals globally each year, with duodenal ulcers accounting for a significant proportion. Also, the rising incidence of gastrointestinal disorders, particularly among the elderly, is boosting the adoption of treatment options such as proton pump inhibitors (PPIs) and H2 receptor antagonists. These medications are recognized for their superior efficacy in reducing gastric acid, promoting mucosal healing, and ensuring patient safety. Combination therapies that include antibiotics targeting Helicobacter pylori, along with ulcer-protective agents such as misoprostol and sucralfate, are increasingly being used to enhance treatment compliance and outcomes.
 

The global surge in Helicobacter pylori infections is further contributing to the demand for both treatment and diagnostic testing. According to the National Institutes of Health (NIH), approximately 50% of the world’s population is affected by H. pylori. Research published by Wiley Online Library also highlights that the prevalence of infection rises with age and often begins within the first decade of life, amplifying the need for early intervention.
 

Moreover, long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) significantly increases the risk of duodenal ulcers due to their damaging effects on the intestinal lining. A study by the NIH reports that 97% of individuals with chronic pain use NSAIDs for more than 21 days, increasing their vulnerability to ulcers and the subsequent demand for effective treatment options.
 

The growing integration of digital health technologies such as telemedicine platforms, mobile health applications, and AI-enabled diagnostics, is also transforming ulcer care. These innovations facilitate early detection and personalized treatment strategies, particularly in underserved areas with limited access to specialist care, thereby improving patient engagement and expanding access to care
 

The duodenal ulcer treatment refers to the medications and treatment methods used in healing of ulcers in the duodenum, which is the first part of the small intestine and helps to prevent their recurrence. The treatment includes addressing the cause of the ulcer, or the use of certain medications to reduce stomach acid and protect the stomach lining. The market focuses on the development, manufacturing, and distribution of therapies for managing and healing duodenal ulcers. These include PPIs, H2 antagonists, antibiotics, antacids, mucosal protectants, P-CABs and surgical solutions.
 

Duodenal Ulcer Treatment Market Trends

• The market is being driven by the rising incidence of gastrointestinal disorders, particularly those associated with Helicobacter pylori infections and the widespread use of nonsteroidal anti-inflammatory drugs (NSAIDs).
   
• A growing emphasis within global healthcare systems on early diagnosis and minimally invasive therapies is contributing to increased demand for safe and effective ulcer management solutions.
   
• Nutritional therapies and probiotic-based treatments are gaining traction for their role in restoring gut health and promoting mucosal healing. These approaches are increasingly incorporated into comprehensive care models, reflecting a broader shift toward wellness-focused strategies in gastrointestinal medicine.
   
• Additionally, the adoption of precision medicine is reshaping treatment protocols by customizing regimens based on individual patient profiles, microbial resistance, and underlying health conditions.
   
• The use of combination therapies, incorporating acid suppression, antimicrobial agents, and mucosal protectants, is improving clinical outcomes and lowering recurrence rates, highlighting the effectiveness of multi-faceted treatment approaches.
   
• There is also a notable transition toward potassium-competitive acid blockers (P-CABs), next-generation acid suppression agents that offer rapid onset and sustained efficacy. These are emerging as preferred alternatives to traditional proton pump inhibitors (PPIs), indicating a move toward more targeted and durable therapeutic options.
   
• Further, the integration of telemedicine and AI-powered gastrointestinal diagnostics is transforming the detection and management of duodenal ulcers. These digital tools facilitate remote consultations, streamline diagnostic processes, and support personalized treatment planning, especially in underserved and rural areas, thereby enhancing access to care and improving patient adherence.
   

Duodenal Ulcer Treatment Market Analysis

In 2021, the global market was valued at USD 2.8 billion. The following year, it saw a slight increase to USD 2.9 billion, and by 2023, the market further climbed to USD 3.1 billion.
 

Based on treatment type, the global market is segmented into pharmacological treatment and surgery. The pharmacological treatment segment accounted for the highest market share and was valued at USD 2.8 billion in 2024. The pharmacological treatment segment is further bifurcated into drug class, medication type, and route of administration.
 

• The growing effectiveness of drug classes such as proton pump inhibitors (PPIs) and H2 receptor antagonists, known for providing rapid and consistent relief by reducing gastric acid production, is driving increased demand for pharmacological treatments. Their ability to reliably control symptoms, combined with ease of administration, has led to a strong consumer preference for these therapeutic options.
   
• The convenience of oral administration and high patient compliance associated with these medications, compared to invasive procedures, support outpatient care and self-management. This further boost demand within the pharmacological treatment segment.
   
• Additionally, the widespread accessibility and affordability of these therapies make them attractive to a broader population, contributing to overall market expansion.
   
• Government-led initiatives that promote pharmacological treatments, particularly those that support home-based recovery and preventive healthcare, are also playing a key role in driving market growth.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on age group, the global duodenal ulcer treatment market is categorized into adults and geriatrics. The geriatrics segment dominated the market with 58.7% market share in 2024.
 

• The high incidence of duodenal ulcers among the elderly is primarily linked to age-related physiological changes, such as diminished mucosal defense, which heightens vulnerability. This demographic trend is fueling the need for long-term treatment and management options.
   
• Older adults frequently manage chronic conditions like cardiovascular disease or arthritis, often requiring extended use of non-steroidal anti-inflammatory drugs (NSAIDs). Prolonged NSAID consumption significantly increases the risk of duodenal ulcer development in this population.
   
• As noted by ScienceDirect, the likelihood of H. pylori infection increases with age and is a key factor in the onset of duodenal ulcers. Therefore, the elevated prevalence of H. pylori infections among the elderly further drives market demand.
   

Based on end use, the global duodenal ulcer treatment market is categorized into hospitals and clinics, homecare settings, ambulatory surgical centers and other end users. The segment hospitals and clinics dominated the market in 2024 and is anticipated to witness growth at a CAGR of 5.1%.
 

• Hospitals and clinics remain the preferred choice for patients seeking diagnosis and treatment of duodenal ulcers, as they provide critical services such as endoscopy, surgical interventions, and specialized care, particularly during emergencies or when advanced medical expertise is needed.
   
• The potential severity and complications associated with duodenal ulcers often require immediate attention and expert monitoring, further solidifying the dominance of hospitals in this market segment.
   
• Furthermore, hospitals offer integrated care through clinical trials, post-treatment follow-ups, and lifestyle management programs, ensuring continuity in medication adherence and preventive strategies. These comprehensive services support both treatment and recovery, positioning hospitals as the leading segment in the duodenal ulcer treatment landscape.
   

The North America duodenal ulcer treatment market dominated the global market with a market share of 53.9% in 2024.
 

The U.S. market was valued at USD 1.36 billion and USD 1.42 billion in 2021 and 2022, respectively. The market size reached USD 1.53 billion in 2024, growing from USD 1.47 billion in 2023.
 

• The market in the U.S. continues to expand, driven by the rising prevalence of gastrointestinal disorders linked to Helicobacter pylori infections, widespread NSAID usage, and unhealthy lifestyle habits.
   
• The U.S. healthcare system places a strong emphasis on early diagnosis and effective ulcer management, supported by advanced diagnostic tools and treatment options. According to Medscape, the prevalence of H. pylori infection in duodenal ulcer cases among non-NSAID users remains high, reflecting a significant patient pool in need of targeted therapy.
   
• Public health initiatives, such as awareness campaigns and routine screenings, alongside a well-established network of hospitals and specialty clinics, further enhance early intervention and access to care.
   
• Continued investments in gastrointestinal health and innovation in treatment protocols strengthen the country’s position in the global market.
   

Europe duodenal ulcer treatment market accounted for USD 731 million in 2024 and is anticipated to show considerable growth over the forecast period.
 

• The increasing awareness and adoption of duodenal ulcer treatment programs in the region, along with rising government initiatives to reduce gastrointestinal disease burden, is anticipated to spur growth in the Europe market.
   
• Advancements in treatment technologies such as acid-suppressing agents and combination therapy methods, along with the introduction of broad-spectrum and cost-effective drug formulations, boosts the requirement of market in the European region.
   
• Also, the presence of key market players in the region strengthens the market. These companies actively participate in innovation through the development of next-generation ulcer therapies, expanded treatment coverage and partnerships with public health agencies, thereby advancing market growth.
   

Germany duodenal ulcer treatment market is anticipated to witness considerable growth over the analysis period.
 

• Germany is expected to witness notable growth in its market, largely due to a high incidence of H. pylori-related ulcers. As per the Medicine Guide, about 150 out of every 100,000 people in the country suffer from duodenal ulcers, with 90% of these linked to H. pylori infections.
   
• The country’s strong healthcare and education systems support the uptake of advanced treatments, with general practitioners playing a central role in delivering care.
   
• Furthermore, national awareness campaigns and proactive healthcare programs have bolstered public understanding of gastrointestinal disorders, improving early detection and treatment outcomes.
   
• Therefore, Germany’s comprehensive approach to ulcer management places it at the forefront of the European market.
   

The Asia Pacific duodenal ulcer treatment market is anticipated to grow at the highest CAGR of 5.4% during the analysis timeframe.
 

• The market in the Asia Pacific region is growing rapidly due to the rise in duodenal ulcer cases, increasing public health awareness, and the improvement of gastrointestinal care infrastructure across both urban and rural populations.
   
• Countries such as China, India, and Japan are adopting duodenal ulcer treatments at a faster rate due to the growing demand for digestive healthcare, government-led screening initiatives, and the rise in hospital-based treatment programs targeting adults and elderly populations.
   
• Additionally, The rapid development of public health clinics, specialized gastroenterology centers, and integration of ulcer management into national health programs are significantly enhancing access to treatment in the region.
   

China duodenal ulcer treatment market is predicted to grow significantly over the forecast period.
 

• China is poised for strong growth in the market, fuelled by a high burden of Helicobacter pylori infections, which affect a significant portion of the population.
   
• Studies indicate that more than 50% of the adult population in China carries H. pylori, with infection rates even higher in rural areas due to lower sanitation and healthcare access. This high prevalence is a major contributor to the increasing incidence of duodenal ulcers, especially in older adults and individuals regularly using NSAIDs.
   
• The country’s healthcare system is responding with large-scale public health initiatives aimed at infection control, early screening, and education. National guidelines now recommend routine testing for H. pylori, especially among high-risk populations, and the widespread implementation of the “test-and-treat” strategy is being adopted across hospitals and primary care settings.
   
• China's ongoing healthcare reform and its Healthy China 2030 plan, which emphasizes prevention and early treatment, are expected to further accelerate growth in the duodenal ulcer treatment landscape.
   

Brazil is experiencing significant growth in the Latin America duodenal ulcer treatment market
 

• With a reported ulcer prevalence of 26.5%, according to the NIH, there is a growing need for effective gastrointestinal therapeutics. The country's aging population accounting neatly 22.2 million elderly individuals as of 2023, further contributes to rising demand, particularly as age-related factors and NSAID use increase susceptibility.
   
• Efforts to deliver affordable and preventive healthcare solutions are accelerating market expansion.
   
• Additionally, government-led awareness campaigns are crucial in reaching low- and middle-income communities, improving access to diagnosis and treatment while promoting public health education.
   

Saudi Arabia duodenal ulcer treatment market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• The expansion of public health clinics, enhanced treatment accessibility, and increased government healthcare spending are all contributing to market growth. As part of its Vision 2030 initiative, the country is investing in healthcare infrastructure with a strong focus on gastrointestinal health, aiming to reduce recurrence and long-term care costs.
   
• The adoption of AI-powered healthcare monitoring systems and emphasis on rapid, efficient treatments further support the market’s development.
   
• Public awareness initiatives around digestive health and preventative care are also instrumental in fostering early intervention and improving patient outcomes.
   

Duodenal Ulcer Treatment Market Share

Competition in the duodenal ulcer treatment industry is marked by well-established companies, emerging firms and local players fighting to capture a larger share of the market. The top 5 players such as AstraZeneca, GlaxoSmithKline, Pfizer, Novartis and Boehringer Ingelheim account for approximately 35% - 40% of the global market. These key players focus on various strategies such as acquisitions, business expansion and novel product launches to consolidate their market presence. Additionally, there are several local and regional players operating in the market who are boosting competition by providing affordable options at lower costs. These players are also involved in several strategies such as mergers, acquisitions, and novel product launches to expand their product offerings.
 

Duodenal Ulcer Treatment Market Companies

Prominent players operating in the duodenal ulcer treatment industry includes:

• Abbott Laboratories
• AstraZeneca
• Boehringer Ingelheim
• Cipla
• Eisai
• Ferozsons Laboratories
• GlaxoSmithKline
• Lupin
• Merck
• Novartis
• Pfizer
• Sanofi
• Sun Pharma
• Takeda Pharmaceutical

• Pfizer is one of the key players in the market due to the broad portfolio of acid-suppressing and mucosal-protective therapies, including famotidine, rabeprazole and Cytotec. The company maintains regulatory approvals across markets and offers both oral and injectable formulations. The company has established manufacturing infrastructure and participate in hospital and retail pharmacy channels to support strong presence in ulcer care.

• Novartis contributes to the market through range of gastrointestinal therapeutics, including proton pump inhibitors and combination therapies caused due to Helicobacter pylori. The company leverages its global research and development and regional partnerships to expand access to ulcer treatments. Novartis is involved in clinical innovation across Europe, Asia-Pacific, and Latin America, advancing in gastrointestinal health solutions.
   

Duodenal Ulcer Treatment Industry News

• In June 2024, Cipla signed an agreement with Takeda Pharmaceutical to commercialize the drug Vonoprazan, a potassium-competitive acid blocker in India for treating disorders such as duodenal ulcer, gastric ulcer, GERD, and Helicobacter pylori. This agreement expanded Cipla’s gastrointestinal portfolio with a next-generation therapy for ulcer and reflux conditions.
   
• In April 2023, Akums Drugs and Pharmaceuticals launched a Combikit in India for the treatment of duodenal ulcers due to Helicobacter pylori infection. The kit includes amoxicillin, clarithromycin, and esomeprazole, for ulcer healing and bacterial eradication. This launch strengthened Akums in the gastrointestinal therapeutics segment.
   
• In February 2023, China’s NMPA approved keverprazan hydrochloride tablets, indicated for the treatment of duodenal ulcer, developed by Jiangsu Carephar Pharmaceutical for marketing. The approval introduced a new therapeutic for acid-related gastrointestinal disorders in the Chinese market.
   

The duodenal ulcer treatment market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Pharmacological treatment
  • Drug class
    • Proton pump inhibitors
    • H2 Antagonists
    • Antibiotics
    • Other drug classes
  • Medication type
    • Branded
    • Generics
  • Route of administration
    • Oral
    • Parenteral
• Surgery

Market, By Age Group

• Adults
• Geriatrics

Market, By End Use

• Hospitals and clinics
• Homecare settings
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE